Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1040066 | 1.00 | AKT1 (0.40) | AKT1KCNA5TBXAS1KMT2AESRRB | |
| SCHEMBL1660808 | 1.00 | AKT1 (0.40) | AKT1KCNA5TBXAS1KMT2AESRRB | |
| SCHEMBL1040067 | 1.00 | AKT1 (0.40) | AKT1KCNA5TBXAS1KMT2AESRRB | |
| SCHEMBL9421149 | 0.85 | HMGCR (0.39) | — | |
| SCHEMBL6320596 | 0.85 | HMGCR (0.39) | — | |
| SCHEMBL6900099 | 0.85 | HMGCR (0.39) | — | |
| SCHEMBL6900093 | 0.85 | HMGCR (0.39) | — | |
| SCHEMBL9420672 | 0.79 | CNR2 (0.40) | — | |
| SCHEMBL9420668 | 0.79 | CNR2 (0.40) | — | |
| SCHEMBL9735655 | 0.76 | KMT2A (0.40) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2419399-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | C T RESOLVE SARL (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8673881-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | SCHWARTZ C ERIC | 2011-10-06 | — | — | US | disclosed |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-1740164-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | Alcon Inc. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105069-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | ALCON, INC. (CH) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101061-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | AKT1 3047/4885KCNA5 4291/4885TBXAS1 163/4885 |
| US-20110245528-A1 | THERAPEUTIC COMPOUNDS | ALOX5, ALOX15B, ALOX12 | AKT1 4125/4885KCNA5 2992/4885TBXAS1 92/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | AKT1 3047/4885KCNA5 4291/4885TBXAS1 163/4885 |
| US-20110098314-A1 | STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA | HMGCR, HMGB2, GRHPR | AKT1 1302/4885KCNA5 3607/4885TBXAS1 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.